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Exosomes: nanoparticles involved in cardioprotection?
Derek M Yellon DSc, Sean M Davidson PhD
Abstract
Exosomes are nano-sized lipid vesicles released from cells. They are capable of transferring proteins,
mRNA and miRNA between cells, and therefore represent a potential means of intercellular
communication. Exosomes can be pro-angiogenic and may have cardioprotective properties. In
contrast, their larger cousins, microvesicles, appear to have generally detrimental effects, being pro-
thrombotic and pro-inflammatory. Exosomes are released from multivesicular bodies via an exocytic
pathway, and have the potential for cell-specific targeting. This normal process is “hijacked” during
various pathological conditions such as cancer, viral infection, and amyloidopathies. We assess the
evidence for a role of exosomes and microvesicles in normal cardiovascular physiology, as well as
during cardiovascular disease. In addition to offering a potential source of cardiovascular
biomarkers, exosomes may offer a non-immunogenic means of manipulating the heart.
Keywords: exosomes, microvesicles, cardiovascular disease, heart, cardioprotection
Abbreviations used: CHD, coronary heart disease; CVD, Cardiovascular disease; EPC, endothelial
progenitor cells; MVB multivesicular bodies; MSC, mesenchymal stem cells; Shh, sonic hedgehog.
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Introduction
Cardiovascular disease (CVD) is the number one cause of death globally. Figures from The World
Health Organization show an estimated 17.3 million deaths from CVD in 2008 alone with a predicted
rise to almost 25 million deaths per annum by 2030. Although mortality from CVD has declined in
the USA over the past 10 years, there is still an average of 2,150 Americans who die from CVD each
day 1. Myocardial infarction remains a major cause of mortality and morbidity. The restoration of
blood and oxygen to the ischemic myocardium under threat of infarction is of paramount
importance, but reperfusion paradoxically exacerbates the cellular damage incurred during the
severe ischemic insult 2. Although modern acute coronary care has significantly improved survival
rates after a heart attack, the sequelae of ischemia and reperfusion injury frequently include
hypertrophy and heart failure. In response, the heart may undergo various metabolic and structural
adaptations including the growth of new vessels (angiogenesis). Factors that can influence or
interrupt either the initial damage or the pathological response are being actively sought after, as
novel means of treatment. Ideally, such treatments should be safe, effective, specific, and for ease of
delivery should be non- or minimally invasive.
Exosomes are extracellular, lipid bilayer vesicles that range from 30 to 100nm in diameter 3, 4. They
arise within endosomal compartments called multivesicular bodies (MVBs), which bud internally to
form intraluminal vesicles. Upon fusion with the plasma membrane, MVBs release their contents
into the extracellular fluid at which point the vesicles are referred to as exosomes (Figure 1).
Secreted exosomes have been isolated from numerous cell lines as well as most bodily fluids
including saliva, urine and plasma 4-7. Although originally ignored as cell “debris”, it is increasingly
evident that exosome release is regulated and occurs via an energy-dependent pathway. Exosomes
are believed to ferry proteins, mRNA and miRNA cargos through the bloodstream and other body
fluids, shielding them from enzymatic degradation – a process which some retroviruses may “hi-
jack” in order to travel beneath the immune system’s “radar” 8. With the recent discovery that
exosomes can deliver their cargos to recipient cells, it has become apparent that they therefore
represent a potential mode of intercellular communication throughout the entire circulatory system
3, 4. This has caused immense interest in the potential of both exosomes and microvesicles to act as
therapeutic agents or as biomarkers of diverse pathological states including Alzheimer’s disease,
viral infection, cancer, and, increasingly, cardiovascular disease 3, 4, 9. Exosomes appear to be present
in extraordinary numbers (~1010 / ml) in the plasma of healthy individuals 5, suggesting a role beyond
pathology. As high as this figure is, it is probably not unreasonable, considering that the platelets
represent a major source of plasma exosomes, and a normal blood platelet count is already on the
order of 108 / ml. Despite this seemingly astronomical number, exosomes are so minute that the
volume contained within 1010 spherical exosomes of 50 nm diameter would be only ~5 nl or 0.0005%
of 1 ml. When prepared for transmission electron micrography, exosomes exhibit a specific -
biconcave or “cup-shape” - morphology (Figure 2), although it is important to recognize that this is
likely to be an artifact of drying during preparation, and that exosomes spheroid in solution.
Exosomes differ from the larger microvesicles (sometimes called microparticles) that are also found
in plasma, in more than just their size. Microvesicles are believed to form by budding off - or
“shedding” - directly from the plasma membrane (Figure 1), and appear to have properties distinct
from those of exosomes 3, 9, 10. In the cardiovascular system microvesicles have predominantly
detrimental effects, including pro-thrombotic, pro-inflammatory, and endothelial-disrupting actions
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11, 12. Numerous studies have found a strong association between elevated numbers of circulating
microvesicles and cardiovascular disease 12, 13. For example, an increase in pro-coagulant
microparticles has been measured in the blood of patients with acute coronary syndromes 14, and an
increase in circulating endothelial microparticles has been shown to be an independent risk factor
for future cardiovascular events15. A recent FACS analysis of blood from 78 patients with ST segment
elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention
(PPCI) found that microvascular obstruction correlated with intracoronary levels of microparticles
originating from both endothelial cells and platelets 16. Microvesicles do have some practical
advantages over exosomes in that they are more straightforward to isolate, are easily quantified
using flow cytometry, and contain significantly more protein per vesicle (due to their size). This
makes microvesicles, an appealing “pond” in which to fish for novel biomarkers. In contrast,
exosomes are below the detection limit of flow cytometry, and require specialized equipment such
as nanoparticle tracking or light scattering for their quantification. However, exosomes represent a
totally distinct population of vesicles from that of microvesicles, and may provide unique
information on cellular status – healthy or otherwise. Also, although research is at an early stage,
they also possess characteristics making them preferable to microvesicles as novel means of
delivering therapeutics, as will be described.
On the optimal method of exosome purification
A “hot topic” in the exosome field remains the optimal method of exosome purification, and
secondly, their characterization (for detailed reviews see 4, 17, 18). Consequently, this topic bears brief
discussion here. There are essentially four main approaches to purification of exosomes, which are
based on immune-affinity capture, size filtration, size exclusion, or ultracentrifugation. While
immune-affinity is regarded as having the advantage of specificity when an appropriate epitope is
available, yields are often quite low 18. In contrast, filtration through a series of filters down to 100
nm pore size followed by centrifugation to concentrate, while yielding quite high protein content,
risks impurity due to the fragmentation of larger microparticles into smaller vesicles under filtration
pressure 17. This may explain why the product of platelets from septic patients purified in such a
manner were found to worsen cardiac function in isolated muscles 19. The use of ultrafiltration has
been less-well explored, but methods such as cross-flow filtration are an efficient way to
concentrate exosomes away from smaller protein contaminants whilst avoiding the hazards of
passage through small apertures at high pressure 20. The most generally accepted method is to use a
well-defined series of serial centrifugation steps which remove cells and microvesicles, followed by
concentration by ultracentrifugation and subsequent density gradient purification 18. It is worth
noting that the optimal method for microvesicle purification is no more well-established, though
efforts to standardize method of collection, centrifugation and transport are being made 21.
Exosome content
Given the variety of methods used to isolate exosomes, characterization of the exosome population
used is essential prior to their analysis. Proteomic analysis of exosomes has identified common
characteristic marker proteins on their surface and in their lumen 4. Typical exosomal marker
proteins include the tetraspanins CD9, CD63, and CD81, and heat-shock proteins such as HSP70 and
HSP90 4. In addition, exosomes typically contain cytoplasmic proteins such as actin, annexins, and
glycolytic enzymes such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and enolase 4. They
also contain molecules involved in MVB biogenesis such as Alix, TSG101 and Rab proteins 4, which
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have shown to be involved in exosome release. It should be appreciated that these exosomes could
transport many, as yet unidentified, proteins and in view of the cardioprotective effects that have
been observed (described below), it could be hypothesized that some would be prosurvival.
Understanding of the mechanism of exosome biogenesis and release is evolving rapidly. Just a few
years ago, evidence favored the release of exosomes by a mechanism independent of the ESCRT
(endosomal sorting complex required for transport) machinery, but requiring the sphingolipid
ceramide 22. With the recent description of a role for syndecan, syntenin, Alix and ESCRTs in the
control exosome formation 23, the balance of evidence is now swinging towards support of an
ESCRT-regulated mechanism of membrane budding of exosomes 23, 24.
A scale diagram using representations of crystallographic structures of some major exosomal
molecules, puts into perspective just how restricted the space is within exosomes (Figure 2).
However, en masse, exosomes might deliver a significant quantity of proteins to effect changes in
recipient cells. Indeed, experiments have shown that exosomes can transfer signaling ligands such as
those of the Notch family from tumors to endothelial cells in quantities sufficient to alter their
morphology 25.
Some of the proteins mentioned above are already known to influence cardioprotection. Indeed, the
relationship of heat-shock protein and cardio-protection was well established in the 1990’s 26. Many
heat shock proteins (including αB-crystallin, HSP60 and HSP70) are secreted in exosomes 27, 28, and in
some instances can be transferred to adjacent cells to confer protection against oxidative stress 29.
Interestingly, circulating HSP70 levels are negatively correlated with symptoms of cardiovascular
disease 30, suggesting exosomal HSP70 may be beneficial. HSP60 is also secreted from
cardiomyocytes in exosomes 31, although the implications of this are unclear, and circulating HSP60
levels have been associated with autoimmune disease 30. Other secreted proteins implicated in CVD
or myocardial ischemia and reperfusion have been identified in exosomes. For example, the
inflammatory cytokine TNFα, which can induce contractile dysfunction, hypertrophy, fibrosis and cell 
death, has been detected in exosomes released from hypoxic cardiomyocytes 32. Interestingly, the
TNF receptor has also been identified in plasma exosomes 33. Other molecules important in the
cardiovascular system identified in exosomes include PPARγ 34, PTEN 35, annexins4, DPPIV4, EGFR 36
and a host of metabolic enzymes 4. The p22 and gp91 subunits of phagocyte-like NADPH oxidase as
well as NAD(P)H oxidase activity has been detected in exosomes derived from platelets of septic
individuals, although the significance of this is not known 37. A recent high-profile publication
demonstrated an evolutionarily conserved role for exosomes in the secretion of Wnt proteins, and in
this case the presentation of Wnt on exosomal surfaces was shown to contribute to biological Wnt
signaling 38. The “Exocarta” database 39 catalogues the proteins that have been identified in
exosomes and also the number of studies in which they have been identified 4, as an important
means of assessing the robustness of this localization. However, it is important to keep in mind that
the majority of studies thus far have been performed on exosomes released from malignant cells,
which may have an abnormal composition.
Plasma exosomes, like microvesicles, originate primarily from platelets and megakaryocytes, and to
a lesser degree endothelial cells, erythrocytes, and leukocytes 10, 12, 13. The exosomal proteome
differs according to the type of cell that released it 4, such that platelet or endothelial exosomes can
be identified by their expression of typical cellular markers such as CD31 (PECAM-1) or CD62P (P-
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selectin) respectively 10. Furthermore, studies indicate that cellular stress can alter exosomal protein
and RNA content 40, suggesting that exosomes represents a snapshot of the physiological state of the
cell - a kind of “status update”, released by cells into the circulation.
In some respects, it is easier to envisage how transfer of even minute quantities of miRNA might
have more extensive effects relative to the transfer of protein. Hence, the discovery that mRNA and
miRNA are also localized within exosomes has generated much interest, although the extent to
which plasma miRNA is contained within exosomes is still controversial. Some reports suggest that
exosomes contain the majority of plasma miRNA41, while others suggest that plasma miRNAs are
mainly found in complexes with carrier proteins such as argonaute 42 or high density lipoproteins 43.
In any event, numerous studies have demonstrated the ability of exosomes (and microvesicles) to
transfer miRNA to recipient cells 44, 45. In a seminal paper in the field, exosomes from mast cells were
shown conclusively to contain both miRNA and mRNA, and to be able to transfer mRNA to recipient
cells for translation into new proteins 44. Importantly, the RNA was shown to be contained within the
exosomes, since it was protected from treatment with RNAse or trypsin 44. The miRNA or mRNA
content of exosomes may also reflect the cell they originate from. The miRNA content of dendritic
cell exosomes varies with cell maturation 46. Similarly, exosomes from mast cells exposed to
oxidative stress contain different mRNAs to those from control cells 47. Furthermore, exosomes from
stressed cells conferred resistance against oxidative stress to recipient cells 47. Another fascinating
report has detailed the use of purified exosomes as an in vivo “transfection reagent” for the delivery
into the brains of mice of miRNA, which had been loaded into the exosomes by electroporation 48.
Exosomal miRNA content may be relevant to CVD. Patients with acute myocardial infarction have
increased serum levels of miR-1 and miR-133a, while in vitro experiments suggest that exosomes
from cardiac cells can release miR-133a and transfer it to recipient cells where it modulates gene
expression 49. Curiously, miR-133a normally suppresses hypertrophy by restraining expression of the
inositol 1,4,5'-triphosphate receptor II (IP(3)RII) calcium channel. Cellular levels of miR-133a have
been found to decrease during the hypertrophic response to pressure overload 50. Clearly much
work remains to be done to clarify to role of exosomes and miRNA in CVD.
In addition to proteins and RNA, exosomes appear to be enriched in sphingomyelins, though levels
of cholesterol and phosphatidyl choline appear to depend on cellular source 51. They can contain
bioactive lipids such as phospholipases, arachidonic acid and derivatives such as prostaglandins 52,
which may exert effects related to inflammation.
Exosomes and cardioprotection
The early promise of stem cells in cardiac regeneration generated much excitement for their
potential to improve function by differentiating into new cardiomyocytes. Despite some waning of
this initial optimism, improvement of cardiac function and survival is consistently observed after
injection of stem cells, apparently due to their release of paracrine factors. An intriguing possibility
which is emerging is that some of these paracrine effects may be mediated by exosomes. For
example, exosomes purified from the conditioned medium of CD34+ stem cells are pro-angiogenic
both in vitro and in vivo 53. Similarly, recent evidence suggests that human embryonic stem cell-
derived MSC, rather than differentiating into cardiomyocytes when injected into recipient hearts,
actually mediate their cardioprotective properties by the paracrine release of exosomes 54. The
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highly purified, protective component from MSC-conditioned medium was found to contain vesicles
of the same density, size, and appearance by electron microscopy as exosomes, and they expressed
exosomal marker proteins (CD9, CD81, Alix)54. The exosomes were highly cardioprotective when
introduced either into Langendorff perfused isolated rat hearts or intravenously into anaesthetized
mice immediately before reperfusion. The mechanism by which they confer cardioprotection
appears to involve activation of the same cardioprotective kinase pathways as preconditioning 54-57.
Furthermore, the cross-species cardioprotection that was observed points to an evolutionarily
conserved pathway.
Exosomes have also been isolated from in vitro-cultured, murine cardiac progenitor cells (CPC) and
recent data suggests that they are equally able to protect the myocardium from IR injury after intra
myocardial delivery 58. On a practical note, it is important that in experiments such as these, cells are
cultured in serum that has been pre-treated (by ultracentrifugation for example) to deplete it of
exosomes. Secondly, it is essential to compare cardioprotection against vehicle containing any
carrier retained during purification, since in our experience, vehicle such as BSA or polyethylene
glycol can cause an apparent decrease in infarct size at high concentration. The question now being
pursued in these studies is the identity of the cardioprotective ligands.
The group of Camussi have undertaken extensive work demonstrating that microvesicles released by
mesenchymal stem cells (MSC) or endothelial progenitor cells (EPC) can prevent acute kidney injury
when injected intravenously following kidney ischemia 59, 60. Interestingly, the isolation protocol used
is similar to the standard ultracentrifugation protocol for exosome purification, and may result in a
mixture of microvesicles and exosomes. These results highlight the importance of careful
characterization and definition of the population of vesicles after isolation. Microvesicles isolated
from ischemic mouse hind limbs have also been found to promote angiogenesis when injected into
naïve ischemic limbs 61. In contrast, microvesicles purified from plasma after a preconditioning
protocol were recently shown not to affect cardiac ischemia and reperfusion injury when injected
intravenously into rats immediately before reperfusion 62. Recently it has been suggested that
plasma exosomes are cardioprotective in a Langendorff perfused heart system 63. Given the many
beneficial aspects of exosomes outlined here, their induction after hypoxia 40, 64, and their ability to
transmit cardioprotective signals, an attractive hypothesis is that exosomes contribute to the
humoral transmission of cardioprotective state induced by cardioprotective modalities such as
remote ischemic preconditioning. If our hypothesis is validated, this would in turn suggest they may
harbor novel cardioprotective molecules.
The mechanism by which exosomes exert cardioprotection is almost entirely unknown. It appears to
involve a direct interaction with cells in the heart, rather than blood components, because
cardioprotection has been observed both in vitro and in vivo. At least in specific cases, exosomes
have been demonstrated to be capable of direct transfer of RNA 44-46 (Figure 3B) or protein (Figure
3A)65. For example, the Notch ligand, Delta-like 4 (Dll4), can be transferred between endothelial cells
via exosomes 25. However, the observation that cardioprotection is rapidly induced after exosome
perfusion, suggests a more immediate mechanism. Remarkably, exosomes/microvesicles derived
from cancer cells are capable of transferring activated EGF receptors directly from malignant cells to
endothelial cells 36 (Figure 3C), which then stimulates angiogenesis via autocrine production of VEGF.
Alternatively, proteins on the surface of exosomes may interact directly with plasma-membrane
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receptors in the myocardium and activate their downstream intracellular signaling pathways (Figure
3D). The majority of the hundreds of G-protein coupled receptors studied to date activate
intracellular signaling pathways which converge on PI-3kinase/Akt and ERK/MAPK, or JAK/STAT - the
so-called “RISK pathway” or “SAFE pathway” of cardioprotection respectively. Interestingly, the
paracrine cardioprotective effect of MSC cells requires PI-3kinase/Akt 66, supporting this hypothesis.
Exosomes and cardiovascular disease
Though the potential therapeutic application of exosomes in CVD is only just beginning to be
explored, results thus far are exciting. Ischemic heart disease develops as a result of coronary
atherosclerotic plaque formation leading to a reduced coronary blood flow. Over a period of time
coronary collateral vessels and microvascular angiogenesis develop as a response to myocardial
ischemia. It is thought that angiogenesis helps preserve the functionality of ischemic myocardium.
Therapeutic coronary angiogenesis and collateralization have tremendous potential as treatment
strategies for patients with ischemic heart disease. There is increasing evidence of exosomes having
an important role in angiogenesis. Human CD34+ stem cell-derived exosomes induce angiogenic
activity in vitro and in vivo 53. Intravenous delivery of exosomes from MSC cells suppressed lung
inflammation, inhibited vascular remodeling and inhibited the development right ventricular
hypertrophy in a mouse model of hypoxic pulmonary hypertension 67. Exosomes from dendritic cells
can modulate immune responses, and injection of exosomes derived from donor bone marrow
dendritic cells was found to modulate response to heart transplantation 68.
In addition to being a major risk factor for CVD, vascular complications are a major contributor to the
morbidity of diabetes mellitus. The potential of exosome to shuttle miRs and proteins to the
ischemic limb in peripheral vascular disease has barely been examined, but a recent study detected
a significant increase in miR-15a and miR-16 levels in the serum of patients with critical limb
ischemia. In addition to being conjugated to argonaute-2, the miRNAs were found to be within
exosomes 69, suggesting their potential as markers of critical limb ischemia. Since miR-15a appears to
inhibit angiogenesis 70, it will be interesting to determine whether exosomes actually contribute to
the ischemic injury in this case. In other situations, the injection of pro angiogenic exosomes can be
beneficial. For example, the previously mentioned vesicles isolated by the group of Camussi 60, have
been shown to induce neovascularization in a murine model of hind limb ischemia 71, stimulating
angiogenesis by means of miRNA or mRNA transfer 72. Protection was lost after RNAse treatment or
depletion of pro-angiogenic miR-126 and miR-296 60, 71. Human cardiomyocyte progenitor cells have
also been shown to release exosomes which can stimulate the migration of microvascular
endothelial cells 73. In an interesting recent study, human umbilical vein endothelial cells subjected
to shear stress were shown to release vesicles (exosomes and/or microvesicles) enriched in miR-
143/145 – which controlled target gene expression in co-cultured smooth muscle cells 45.
Importantly, the released vesicles reduced atherosclerotic lesion formation in a mouse model of
atherosclerosis 45.
Many of the studies performed so far utilize vesicles purified from cells cultured in vitro, which may
have a different lipid composition, protein content or other characteristics from those released in
vivo. Thus while they demonstrate a potentially useful therapeutic effect, they don’t address the
fundamental question of the in vivo relevance of the native endogenous vesicles. This is difficult to
determine without effective and specific tools to prevent microvesicle or exosome release in vivo.
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There are some exciting leads in this area, with the Rab proteins being implicated in exosome
release 74, however the exact contingent of Rab proteins involved are suspected to be cell-type
specific, and requires much more investigation. Similarly, the existence of a mechanism controlling
the cell-specific delivery of exosomes is not well established. A recent report suggests that selectivity
of uptake is regulated by specific interactions between tetraspanins and integrins and can be
controlled by altering the expression of different tetraspanins proteins 75. This raises the possibility
that the capacity for “targeting” of exosomes can be harnessed for delivery to specific cells or organs
but again, much work remains to be done in this area. This and other basic aspects of exosome
biology will be necessary to understand before their clinical application can be seriously considered.
The future potential of exosomes in cardiovascular research
Two obvious avenues for the potential exploitation of exosomes in the cardiovascular field are in
their use as biomarkers, and in the potential for harnessing their capacity for delivery of biologics
(Figure 4). A major advantage of using secreted vesicles such as exosomes for the proteomic
identification of plasma biomarkers is that simply by purifying them, many possible cellular proteins
of interest are separated from the morass of highly abundant serum proteins 4. This greatly
simplifies subsequent proteomic analysis 4. Although research is still at a very early stage, the view is
emerging that exosomes represent a “snapshot” of the (primarily cytosolic and plasma membrane)
cellular proteome of their cell of origin 4. In terms of biomarker screening, a simple approach may be
to analyze exosomes secreted in the urine, which may reflect the protein or miRNA changes that
occur with CVD. This possibility has been demonstrated by the finding that there is a dramatic
increase in the levels of exosomal miR-1 in the urine of rats and humans after acute myocardial
infarction 76.
A second avenue for exploitation might lie in the development of reagents for the delivery of
biologics to cells using exosomes – which are essentially “natural liposomes”. The capacity for
exosomes to be experimentally manipulated for the delivery of specific proteins has been
demonstrated by engineering CD34+ stem cells to release exosomes containing the pro-angiogenic
factor, sonic hedgehog (Shh). Injection of the modified CD34Shh cells into the border zone of mice
after myocardial infarction reduced infarct size, increased capillary density, and improved long-term
functional recovery 65. Functional transfer of Shh protein was demonstrated to occur in vitro65, but
may prove difficult to confirm in vivo. Similarly, exosomes produced by dendritic cells have been
isolated and loaded with specific siRNA, then used to deliver knock down BACE1, a therapeutic
target in Alzheimer’s disease, in the brains of mice 48. Targeting in this case was achieved by
expressing a neuron-specific peptide.
Exosomes have a number of characteristics that appear to make them preferable to microvesicles
for the purpose of therapeutics, including lower immunogenicity 3. On the other hand , there is
evidence that some exosomes express the pro coagulant protein, tissue factor (TF) and may be pro
coagulant, e.g.: exosomes purified from mesenchymal-like cancer cells 77, hypoxic glioblastoma cells
78, and bronchial epithelial cells, particularly after pressure-stress 79. An earlier study described a pro
coagulant activity in exosomes from mast cells 80, however since these vesicles were isolated without
an intermediate centrifugation step to remove microvesicles, it is likely that pro coagulant
microvesicles contributed to the activity observed 80. In contrast to these examples, exosomes from
various sources including tumors, immune cells, and body fluids have been found to be
CIRCRES/2012/300636/R10
10
immunosuppressive 3. These contrasting data emphasize once again the importance of carefully
defining the vesicle population being examined, and, of the peril of generalizing in a field where
many of the basic characteristics are still being elucidated and defined.
Finally, a further avenue for exploitation might be in developing the means to stimulate the body’s
own production and transport of exosomes that have been programmed for survival, and which may
therefore be of direct benefit to patients with CVD.
Conclusion
Interest in exosomes is exploding, with more papers on exosomes published since 2010 than in all
previous years combined, and yet, much about their basic biology remains to be determined. By
analogy with astronomy, exosomes represent a kind of “dark matter” of the body – invisible to direct
microscopy, but whose existence can be inferred by the effects they have on other cells. The
question now is just how pervasive is their influence? Certainly, they have been strongly implicated
in cancer, and in certain, specific situations such as retroviral budding and transmission, but do these
exosomes represent the “dark side” of a normal physiological process? If exosomes, present in
plasma at such extraordinary concentrations, are able to transfer protein and RNA to recipient cells
in significant quantities, they might represent a new paradigm of intercellular signal transmission. As
such, exosome biology could represent a new frontier, at the nanoscale, which will advance our
search for novel approaches to cardiovascular signaling and cardioprotection. Though the basic
aspects of exosome biology are only just beginning to be explored, it seems certain that in the near
future they will be generating a level of interest disproportionate to their size.
Figure legends
Figure 1. Microvesicles are released via plasma membrane shedding, in contrast to the directed
release of exosomes from multivesicular bodies (MVB) that fuse with the plasma membrane.
Exosomes form by invagination of the MVB membrane. Like microvesicles, they engulf cytosolic
contents, and therefore might be thought of as “status updates” released from the cell.
Figure 2. (Left) A diagram of a 50 nm exosome with lipid bilayer with 3D structures of typical
associated molecules: CD81 (the extracellular domain only is shown) 81 ; hsp70 (currently the most
commonly identified exosomal protein in the Exocarta database of exosomal proteomic studies)4 ;
and siRNA. All elements are drawn to scale, to illustrate the compactness of the exosome. (Right)
Electron micrograph of exosomes from rat plasma (SD unpublished data).
Figure 3. Some of the various ways in which exosomes may affect recipient cells. (A) Protein ligands
in the exosome’s membrane may activate receptors and downstream signaling pathways in recipient
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cells. (B) Exosomes may contain activated receptors which are transferred. Exosomes contain
protein (C), or miRNA and/or mRNA (D), which may be transferred to recipient cells.
Figure 4. Potential uses for exosomes in the cardiovascular field. Exosomes represent potential
sources of diagnostic biomarkers. Alternatively, exosomes may potentially be harvested from plasma
(autologous) or cell culture (exogenous) and exploited for their signaling capacity or for the delivery
of biologics.
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